These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. [Endogenous and exogenous determinants in the evaluation of carcinogenic risks]. Rüdiger HW Offentl Gesundheitswes; 1990 May; 52 Suppl 1():19-22. PubMed ID: 2141677 [No Abstract] [Full Text] [Related]
44. Design of cancer assays for pharmaceutical agents: a reply. Boorman GA; Huff JE; Schwetz BA J Natl Cancer Inst; 1986 Aug; 77(2):589-90. PubMed ID: 3461218 [No Abstract] [Full Text] [Related]
45. Testing for carcinogenicity and the problem of pseudocarcinogenicity. Roe FJ Nature; 1983 Jun 23-29; 303(5919):657-8. PubMed ID: 6855914 [No Abstract] [Full Text] [Related]
46. Experimental tumours and their counterparts in man: some similarities and differences. Carter RL Br J Cancer; 1980 Mar; 41(3):494. PubMed ID: 7387840 [No Abstract] [Full Text] [Related]
47. Bioassays for carcinogenicity in animals. Assays for initiating and promoting activities. Bannasch P; Griesemer RA; Anders F; Becker R; Cabral JR; Della Porta G; Feron VJ; Henschler D; Ito N; Kroes R IARC Sci Publ; 1986; (83):103-26. PubMed ID: 3305339 [No Abstract] [Full Text] [Related]
48. Summary of carcinogenicity data generated by the National Cancer Institute/National Toxicology Program. Di Carlo FJ; Fung VA Drug Metab Rev; 1984; 15(5-6):1251-73. PubMed ID: 6525963 [No Abstract] [Full Text] [Related]
49. [Testing of chemical substances, especially drugs, for carcinogenic activity in mammals (author's transl)]. Schramm T; Teichmann B; Horn KH Arch Geschwulstforsch; 1976; 46(6):506-14. PubMed ID: 999459 [TBL] [Abstract][Full Text] [Related]
50. News about carcinogens: what's fit to print. Bloom BR Hastings Cent Rep; 1979 Aug; 9(4):5-7. PubMed ID: 489277 [No Abstract] [Full Text] [Related]
51. Uncertainty estimates for low-dose-rate extrapolations of animal carcinogenicity data. Guess H; Crump K; Peto R Cancer Res; 1977 Oct; 37(10):3475-83. PubMed ID: 908002 [No Abstract] [Full Text] [Related]
52. The impact of toxicity on carcinogenicity studies: implications for risk assessment. Hoel DG; Haseman JK; Hogan MD; Huff J; McConnell EE Carcinogenesis; 1988 Nov; 9(11):2045-52. PubMed ID: 3052903 [TBL] [Abstract][Full Text] [Related]
53. Comparisons of human cancer potency projections for dieldrin based on human data with those based on animal data. Sielken RL; Stevenson DE Prog Clin Biol Res; 1992; 374():295-319. PubMed ID: 1620708 [No Abstract] [Full Text] [Related]
54. Systematic carcinogen testing through the decision point approach. Williams GM; Weisburger JH Annu Rev Pharmacol Toxicol; 1981; 21():393-416. PubMed ID: 7016010 [No Abstract] [Full Text] [Related]
56. [Preventive implications of cancer multistaging]. Zamfir G Rev Med Chir Soc Med Nat Iasi; 1987; 91(1):9-13. PubMed ID: 3659663 [No Abstract] [Full Text] [Related]
57. Drug metabolism: an industrial research view of the future. Ober RE Drug Metab Rev; 1979; 10(2):315-9. PubMed ID: 551917 [No Abstract] [Full Text] [Related]
58. [Apropos of the article: "Cost of studies on the carcinogenic effects of chemical compounds in animal experiments"]. Kosoĭ GKh Vopr Onkol; 1988; 34(2):240-1. PubMed ID: 3348016 [No Abstract] [Full Text] [Related]